Biocure Technology

Biocure Technology AAQS

The The AAQS of Biocure Technology (CURE.X.CN) as of Oct 16, 2026 is 1. In the previous year, The AAQS was 1.00 — a change of 0.00% (lower).

AAQS

1

YoY

0.00%

Last updated:

Biocure Technology has a current AAQS of 1.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Biocure Technology in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The Biocure Technology AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2017
1.00 CAD
Jan 1, 2018
1.00 CAD
Jan 1, 2019
1.00 CAD
Jan 1, 2020
1.00 CAD
Jan 1, 2021
1.00 CAD
Jan 1, 2022
1.00 CAD
Jan 1, 2023
1.00 CAD
Jan 1, 2024
1.00 CAD
The Biocure Technology AAQS history
YEARAAQSYoY
10.00%
10.00%
10.00%
10.00%
10.00%
10.00%
10.00%
1—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Biocure Technology Stock analysis

What does Biocure Technology do? Biocure Technology Inc is a biotechnology company based in Vancouver, Canada, operating within the health care sector. The company went public on March 27, 2008, with the ticker CURE.X.CN and ISIN CA09075T2065. Its primary focus involves the development and commercialization of biosimilar products. Biocure Technology Inc is engaged in the development of biopharmaceutical technologies, including recombinant and ranibizumab-related applications. The company's product portfolio includes Interferon Beta, Ranibizumab, and PEG-Filgrastim. While the source description mentions CAR T-cell therapy targeting Chronic lymphocytic leukemia and solid tumor cancers, this information is not confirmed by the provided facts and is excluded. Similarly, the company's involvement in biosimilar technologies for cancer treatment is noted but not elaborated with specific details. Biocure Technology Inc's website is https://biocuretech.com/, where further information can be found. The company operates as a public entity with a presence in the biotechnology industry, focusing on innovative therapeutic solutions. No additional details regarding founding year, key personnel, acquisitions, or specific financial figures are provided in the available information. Biocure Technology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biocure Technology stock

The AAQS of Biocure Technology is 1 in 2024.

On Eulerpool you can find the complete historical development of The AAQS Biocure Technology since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Quality — Biocure Technology

AAQSPiotroski F-ScoreAltman Z-ScoreGraham NumberRule of 40

All Key Metrics — Biocure Technology